Cullinan Oncology Inc. (CGEM): Price and Financial Metrics


Cullinan Oncology Inc. (CGEM): $11.48

0.92 (+8.71%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CGEM to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CGEM POWR Grades


  • CGEM scores best on the Value dimension, with a Value rank ahead of 55.59% of US stocks.
  • The strongest trend for CGEM is in Quality, which has been heading down over the past 179 days.
  • CGEM's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

CGEM Stock Summary

  • Cullinan Oncology Inc's stock had its IPO on January 8, 2021, making it an older stock than merely 1.3% of US equities in our set.
  • The ratio of debt to operating expenses for Cullinan Oncology Inc is higher than it is for about merely 0.5% of US stocks.
  • CGEM's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 5.62% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Cullinan Oncology Inc are ARWR, ALLO, BCAB, DNLI, and CLNN.
  • CGEM's SEC filings can be seen here. And to visit Cullinan Oncology Inc's official web site, go to www.cullinanoncology.com.

CGEM Valuation Summary

  • 500 - Internal server error
  • Over the past 34 weeks, CGEM's price/sales ratio has gone down 1.2.
  • CGEM's price/sales ratio has moved down 0.1 over the prior 34 weeks.

Below are key valuation metrics over time for CGEM.

Stock Date P/S P/B P/E EV/EBIT
CGEM 2021-08-31 NA 2.7 -23.7 -21.3
CGEM 2021-08-30 NA 2.8 -24.8 -22.5
CGEM 2021-08-27 NA 2.7 -24.1 -21.7
CGEM 2021-08-26 NA 2.6 -23.0 -20.7
CGEM 2021-08-25 NA 2.6 -22.5 -20.1
CGEM 2021-08-24 NA 2.8 -24.9 -22.6

CGEM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CGEM has a Quality Grade of C, ranking ahead of 34.93% of graded US stocks.
  • CGEM's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows CGEM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2020-12-31 0 NA -1.549

CGEM Price Target

For more insight on analysts targets of CGEM, see our CGEM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $51.75 Average Broker Recommendation 1.38 (Strong Buy)

CGEM Stock Price Chart Interactive Chart >

Price chart for CGEM

CGEM Price/Volume Stats

Current price $11.48 52-week high $37.66
Prev. close $10.56 52-week low $7.30
Day low $10.53 Volume 572,000
Day high $11.64 Avg. volume 385,032
50-day MA $11.01 Dividend yield N/A
200-day MA $17.32 Market Cap 514.11M

Cullinan Oncology Inc. (CGEM) Company Bio


Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Management, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.


CGEM Latest News Stream


Event/Time News Detail
Loading, please wait...

CGEM Latest Social Stream


Loading social stream, please wait...

View Full CGEM Social Stream

Latest CGEM News From Around the Web

Below are the latest news stories about Cullinan Oncology Inc that investors may wish to consider to help them evaluate CGEM as an investment opportunity.

Investors in Cullinan Oncology (NASDAQ:CGEM) have unfortunately lost 66% over the last year

The nature of investing is that you win some, and you lose some. Anyone who held Cullinan Oncology, Inc. ( NASDAQ:CGEM...

Yahoo | February 12, 2022

Cullinan Oncology to Present at SVB Leerink''s 11th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ: CGEM ) ("Cullinan") today announced that it will be participating in SVB Leerink''s 11 th Annual Global Healthcare Conference, being held virtually February 14-18, 2022. Nadim Ahmed, Cullinan''s Chief Executive Officer, will participate in a fireside chat on Thursday, February 17 th at 8:40 a.m. ET A live webcast of the fireside chat will be available via the … Full story available on Benzinga.com

Benzinga | February 7, 2022

Cullinan Oncology to Present at SVB Leerink’s 11th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that it will be participating in SVB Leerink’s 11th Annual Global Healthcare Conference, being held virtually February 14-18, 2022. Nadim Ahmed, Cullinan’s Chief Executive Officer, will participate in a fireside chat on Thursday, February 17th at 8:40 a.m. ET A live webcast of the fireside chat will be available via the Events section of the Company’s investor relations website

Yahoo | February 7, 2022

Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment

Collaboration to identify and advance best-in-class HPK1 protein degraders Exclusive option for Cullinan to license related intellectual property from the collaboration CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, today announced the Company has entered into a collaboration agreement with the Icahn School of Medicine at Mo

Yahoo | January 10, 2022

Cullinan Oncology to Present at Upcoming Virtual Investor Conferences

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that it will present at the following virtual healthcare conferences in January: 40th Annual J.P. Morgan Healthcare Conference Thursday, January 13 at 7:30 a.m. ET HC Wainwright BioConnect Conference Presentation available on-demand for registered conference attendees beginning Monday, January 10 at 7:00 a.m. ET A live webcast of the J.P. Morgan presentation will be available v

Yahoo | January 5, 2022

Read More 'CGEM' Stories Here

CGEM Price Returns

1-mo 12.55%
3-mo -20.83%
6-mo -36.99%
1-year -61.85%
3-year N/A
5-year N/A
YTD -25.60%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0945 seconds.